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Abstract
Background: Huntington’s disease (HD) is an inherited neurodegenerative disorder characterized by cortico-striatal
dysfunction and loss of glutamate uptake. At 7 weeks of age, R6/2 mice, which model an aggressive form of
juvenile HD, show a glutamate-uptake deficit in striatum that can be reversed by treatment with ceftriaxone, a
b-lactam antibiotic that increases GLT1 expression. Only at advanced ages (> 11 weeks), however, do R6/2 mice
show an actual loss of striatal GLT1. Here, we tested whether ceftriaxone can reverse the decline in GLT1
expression that occurs in older R6/2s.
Results: Western blots were used to assess GLT1 expression in both striatum and cerebral cortex in R6/2 and
corresponding wild-type (WT) mice at 9 and 13 weeks of age. Mice were euthanized for immunoblotting 24 hr
after five consecutive days of once daily injections (ip) of ceftriaxone (200 mg/kg) or saline vehicle. Despite a
significant GLT1 reduction in saline-treated R6/2 mice relative to WT at 13, but not 9, weeks of age, ceftriaxone
treatment increased cortical and striatal GLT1 expression relative to saline in all tested mice.
Conclusions: The ability of ceftriaxone to up-regulate GLT1 in R6/2 mice at an age when GLT1 expression is
significantly reduced suggests that the mechanism for increasing GLT1 expression is still functional. Thus,
ceftriaxone could be effective in modulating glutamate transmission even in late-stage HD.
Background
Ample evidence indicates that the neuropathology asso-
ciated with Huntington’s disease (HD), an autosomal
dominant condition characterized by behavioral, cogni-
tive, and physical deterioration, involves the dysregula-
tion of glutamate, an excitatory amino acid [1-4]. In
fact, a decline in glutamate removal has been observed
in the brains of transgenic mouse models of HD [5-7] as
well as HD patients post-mortem [8]. Loss of glutamate
uptake leads to accumulation of extracellular glutamate,
making neurons vulnerable to excitotoxicity. Interest-
ingly, GLT1, a protein expressed primarily on glial cells
and responsible for the removal of most extracellular
glutamate [9,10], appears to be dysfunctional in HD
mouse models [5,6,11]. We recently reported that the
deficit in glutamate uptake in the commonly used R6/2
model at 8 weeks of age can be reversed following
treatment with ceftriaxone [7], a beta-lactam antibiotic
that elevates the level of GLT1 without altering the
expression of other glutamate transporters [12]. By up-
regulating GLT1, ceftriaxone appears to overcome a
functional GLT1 deficit since the level of protein does
not decline until R6/2 mice exceed 11 weeks of age
[5,6,11]. Here, we determined if ceftriaxone could
increase GLT1 expression even in R6/2 mice that have a
deficit in GLT1 production. We focused on cerebral
cortex and striatum, two forebrain regions that show
the greatest HD neuropathology [13,14]. Our results
suggest that the cellular machinery by which ceftriaxone
increases cortical and striatal GLT1 expression is still
intact even in late-stage HD.
Methods
Animals
Male transgenic R6/2 mice (B6CBA-TgN[HDexon1]
62Gpb) and wild-type (WT) controls were obtained
from The Jackson Laboratories (Bar Harbor, ME) at 6
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weeks of age. All mice were housed individually in the
departmental animal colony under standard conditions
(12 hr light/dark cycle with lights on at 07:00 AM) with
access to food and water ad libitum. Both the housing
and experimental use of animals followed the National
Institutes of Health guidelines and were approved by the
Institutional Animal Care and Use Committee at Indi-
ana University Bloomington.
Genotype and CAG repeat length
We used PCR for genotyping and characterizing the
CAG repeat length as previously reported [7]. Our R6/2
mice had 121 ± 1.8 (mean ± SEM) CAG repeats, which
is within the range for developing the HD behavioral
phenotype [15].
Treatment protocol
R6/2 and WT mice at either 8 or 12 weeks of age were
weighed and injected ip with 200 mg/kg ceftriaxone
(Sigma, St. Louis, MO) or an equal volume of saline
once daily for 5 consecutive days. Twenty-four hours
after the last injection, when the mice had reached 9 or
13 weeks of age, the animals were decapitated. Their
brains were removed, and cerebral cortex and striatum
from both hemispheres were dissected and frozen for
immunoblotting.
Western blot
Western blots for GLT1 detection were performed as
previously described [7,16]. In brief, extracted proteins
were separated in 4-20% glycine gel (Invitrogen). The
membranes were blocked in 3% milk in TBST (50 mM
Tris HCl; 150 mM NaCl, pH7.4; 0.1% Tween20) for 30
min at room temperature. The membranes were then
incubated with guinea pig anti-GLT1 antibody (Milli-
pore Bioscience Research Reagents) at 1:5,000 dilution
in blocking buffer at 4˚C. After washing and blocking,
the membranes were incubated with horseradish peroxi-
dase (HRP)-labeled anti-guinea pig secondary antibody
(1:10,000 dilution) in the blocking buffer. Protein load-
ing was normalized using b-tubulin immunoblotting as
a loading control. Chemiluminescent detection of HRP
(SuperSignal West Pico; Pierce) was followed by expo-
sure of the membranes to a Kodak BioMax MR film
(Thermo Fisher Scientific). The films were developed on
an SRX-101A machine. Digitized images of immunor-
eactive proteins were quantified using an MCID system.
The data are reported as percentage ratios of GLT1/b-
tubulin.
Statistical analysis
Data were analyzed by means of a two-way analysis of
variance (ANOVA) and Bonferroni post hoc tests. All
statistical tests required a level of significance of at least
P < 0.05.
Results
Body weights
Table 1 shows the mean body weight of all groups on
the last day of treatment. No significant differences were
found between genotype (WT and R6/2) or treatment
group (ceftriaxone and saline) at 9 weeks of age. Regard-
less of treatment, however, there was a significant
reduction in body weight in R6/2 relative to WT mice
(P < 0.001) at 13 weeks of age, which supports previous
evidence that at this age R6/2 mice are strongly sympto-
matic [17].
Effects of ceftriaxone treatment in cortical and striatal
GLT1 expression
Although saline-treated R6/2s showed no loss of either
cortical or striatal GLT1 relative to WT at 9 weeks of
age (Figure 1), there was a marked reduction in both
brain regions in similarly treated 13-week-old R6/2s
(Figure 2). Quantitative analysis of this age group
revealed significant genotypic differences in GLT1
expression in both cerebral cortex (P < 0.01) and stria-
tum (P < 0.03). Despite the loss of GLT1 in older R6/2s,
these animals showed the same response to ceftriaxone
as the younger R6/2s and both WT age groups. Thus,
WT and R6/2 mice at either 9 (Figure 1) or 13 weeks of
age (Figure 2) responded to ceftriaxone with an increase
in cortical and striatal GLT1 expression relative to sal-
ine. Quantitative analysis revealed a significant effect of
ceftriaxone in both brain regions at 9 and 13 weeks of
age (P < 0.0001 in each case).
Discussion
Our results not only confirm the ability of ceftriaxone to
elevate GLT1 expression in cortex and striatum of R6/2
mice, but show that this effect still occurs even after
GLT1 levels begin to decline when these mice are 13
weeks of age and severely symptomatic. Thus, it appears
that the cellular machinery underlying the ceftriaxone-
induced increase in GLT1 expression is operative in
late-stage HD.
Table 1 Body weight
Age WTs R6/2s WTc R6/2c
9-week 27.53 ± 1.18
(N = 4)
26.52 ± 1.02
(N = 4)
27.27 ± 1.02
(N = 4)
28.06 ± 1.18
(N = 4)
13-week 34.3 ± 2.75
(N = 5)
*26.78 ± 1.69
(N = 5)
33.00 ± 0.98
(N = 5)
*24.52 ± 2.33
(N = 5)
Data are presented as mean body weight (g) ± SEM. * P < 0.001, HD
compared to their respective WT. Abbreviations: WTs and R6/2s indicate saline
treatment, and WTc and R6/2c indicate ceftriaxone treatment. N refers to
number of animals per group.
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Although the mechanism by which ceftriaxone
increases GLT1 expression is not clear, there is support
for activation of nuclear factor-kappa B (NF-kB), a tran-
scription factor that plays a role in regulating immune
responses and cell survival [18]. Translocation of the
NF-kB complex to the cell nucleus appears to be critical
for the action of ceftriaxone [19], and our results sug-
gest that this mechanism is intact in both cortex and
striatum of R6/2 mice regardless of age. Even before the
decline in GLT1 expression, moreover, 8-week-old R6/2
mice have a deficit in glutamate uptake, which is
reversed by ceftriaxone treatment [7]. Although there is
no GLT1 protein deficit at this age, mRNA levels are in
decline [6] and glutamate uptake is reduced [7], suggest-
ing a loss of transporter function well in advance of pro-
tein down-regulation. Thus, ceftriaxone is capable of
overcoming a deficit in GLT1 function. It is interesting
in this regard that palmitoylation, a process by which
proteins are inserted into cellular membranes [20], is
reduced in HD mice, including palmitoylation of GLT1
[21]. Whether ceftriaxone increases GLT1 palmitoyla-
tion is the focus of ongoing research.
It is unlikely that other glutamate transporters can
account for a ceftriaxone-induced increase in glutamate
uptake since ceftriaxone acts selectively on GLT1 [12].
It also is unlikely that loss of other glutamate transpor-
ters can account for the decline in uptake since neither
mRNA nor protein levels are altered for GLAST and
EAAC1 in HD models even at ages when the behavioral
phenotype is severe [6]. Post-mortem analysis of HD
patients, moreover, shows a selective decline in GLT1
mRNA expression [22] as well as a loss of glutamate
uptake [8]. Nevertheless, we cannot rule out the possibi-
lity that ceftriaxone has other actions that may indirectly
impact glutamate transmission, including a change in
dopamine or GABA dynamics. Although an antibiotic
action of ceftriaxone is unlikely in that none of our ani-
mals showed signs of sepsis, it would be useful in fol-
low-up studies to determine if non-antibiotics that also
up-regulate GLT1, such as GPI-1046 [23], mimic the
effects of ceftriaxone in R6/2 mice.
Increasing GLT1 expression may become an effective
HD treatment strategy in that the up-regulation of
GLT1 induced by ceftriaxone significantly improves the
Figure 1 Effects of ceftriaxone on GLT1 expression in cerebral cortex and striatum at 9 weeks of age. Immunoblots (A, C) and
quantitative analysis (B, D) of the percentage ratio of GLT1/b-tubulin in cerebral cortex and striatum, respectively (***P < 0.001 and **P < 0.01
relative to corresponding saline group). Error bars indicate SEM. (N = 4 for each group).
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behavioral phenotype in 8-week-old R6/2 mice [7]. It is
unlikely that starting ceftriaxone treatment in 13-week-
old R6/2s will result in behavioral improvement given
the stage of disease progression in these animals, and in
fact, we found that ceftriaxone failed to reverse the
decline in body weight, which is evident in R6/2s at this
age. But our results suggest that the increase in GLT1
expression that occurs when ceftriaxone treatment is
begun earlier will continue to occur even in late-stage
HD. Thus, GLT1 expression is likely to be an effective
therapeutic target over a relatively long time course.
Glutamate dysregulation, including a possible decline
in GLT1 activity, may play a role in several neurodegen-
erative diseases [5,24]. In fact, a phase III clinical trial of
ceftriaxone for treatment of amyotrophic lateral sclerosis
(ALS) is already underway (for review see [25]). The
dose required to increase GLT1 in mice produces com-
parable levels of ceftriaxone in the central nervous
system of patients undergoing treatment for meningitis
(0.3-6 μmol/L) [26], indicating that our treatment proto-
col is within normal limits for this drug. Nevertheless, it
is interesting that ceftriaxone increased cortical and
striatal GLT1 expression in both R6/2 and WT mice.
WT mice, however, show no discernable behavioral con-
sequences [7], suggesting that mechanisms are in place
to compensate for increased glutamate removal.
Whether HD mice lack these mechanisms or simply
benefit from an increased rate of glutamate uptake
remains to be determined. It appears that within limits
increased GLT1 expression is not a problem, but
decreased expression, which occurs in HD, is.
Conclusions
Ceftriaxone treatment enhances GLT1 expression in
cerebral cortex and striatum of R6/2 mice at 13 weeks
of age when endogenous GLT1 levels decline. These
Figure 2 Effects of ceftriaxone on GLT1 expression in cerebral cortex and striatum at 13 weeks of age. Immunoblots (A, C) and
quantitative analysis (B, D) of the percentage ratio of GLT1/b-tubulin in cerebral cortex and striatum, respectively (**P < 0.01 and ***P < 0.001
relative to corresponding saline group). Note the reduction in the percentage ratio of GLT1/b-tubulin expression in cerebral cortex (**P < 0.01)
and striatum (*P < 0.05) of saline-treated R6/2 mice relative to saline-treated WT mice, and the elimination of this effect after ceftriaxone. Error
bars indicate SEM. (N = 5 for each group).
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data suggest that the mechanism for increasing GLT1
expression is still functional even in late stage HD.
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